MOASC has a new address! Please make changes to your directory. |
|
Mail and Letters
MOASC
PO Box 400606
Hesperia, CA 92340
|
|
Packages and Magazines
MOASC
17240 Olive Street, Box 400606
Hesperia, CA 92340
|
|
-
MOASC is excited to invite you to a virtual award presentation, Blazing Trails & Saving Lives – California's Early Detection Leadership Award, dedicated to Representative Raul Ruiz (D-Palm Desert) on Monday, August 22 at 1:00 PM-PT. As one of the original bill cosponsors, Representative Ruiz has been instrumental in leading H.R. 1946, which will ensure access to innovative multi-cancer screening technologies for Medicare beneficiaries. The award presentation will be an opportunity to engage with and thank the Representative directly, as well as show a groundswell of statewide support for the bipartisan legislation. Please contact moasc@moasc.org if you are interested in participating in this virtual award presentation.
-
Thank you for your participation in the July Lung Cancer Webinar Series presentation on “Adjuvant Therapy in Non-Small Cell Lung Cancer," moderated by Hatim Husain, M.D., Medical Oncologist, Associate Professor of Medicine, UC San Diego Health, with Ani S. Balmanoukian, M.D., Hematologist/Oncologist, Cedars-Sinai-The Angeles Clinic and Research Institute and Jonathan Goldman, M.D., Associate Professor, UCLA Hematology & Oncology Associate Director of Drug Development, Director of Clinical Trials in Thoracic Oncology.
|
|
-
MOASC presents FOTIVDA®(tivozanib) Efficacy, Safety, and Use for Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma (rrRCC) Following 2 or More Prior Systemic Therapies, Thursday, August 25, 2022, 5:30pm-PDT.
|
|
-
MOASC, in partnership with the UCI Hematology/Oncology Fellowship Program and Faculty, has organized a LIVE learning symposia, Spotlight On Clinical Oncology, Saturday, August 27, 2022, 1:00pm to 7:00pm-PDT. This program will cover timely updates in clinical practice, research & development and technology & drug advancements in the field of medical oncology. Oncology experts will discuss innovations in the diagnosis and management of complex oncology issues, including highlights from the Annual ASCO meeting. This Activity is approved for AMA PRA Category 1 Credits™.
|
|
-
MOASC presents Treatment of Unresectable Stage 3 Non-Small Cell Lung Cancer, Wednesday August 31, 6pm PT. This event is part of MOASC’s monthly, virtual Lung Webinar Series. These, 60-minute, educational webinars provide updates in clinical practice, research & development, technology & drug advancements in the treatment of Lung Cancer.
|
|
-
Register for ANCO’s ASCO22 Highlights, August 27.
|
|
-
City of Hope outpatient cancer center celebrates completion in Irvine. The four-story cancer center will be ready to start welcoming visitors before the end of August.
|
|
- Medicare poised to negotiate drug prices in three years.
|
|
- CMS' proposed 2023 Medicare physician fee schedule rule would incentivize health care providers to participate in accountable care organizations.
|
|
-
The CMS is soliciting public comments on how it can improve the Medicare Advantage program, particularly how it can help beneficiaries receive more equitable, person-centered and high-quality care that is sustainable and affordable. The agency said it will use the feedback from health plans and other stakeholders to guide MA policy development and implementation.
|
|
-
Providers and payers are increasingly addressing the health-related social needs (HRSNs) of their patients to improve outcomes, reduce costs, and address health disparities. In a blog post published in Health Affairs yesterday, CMS examines lessons learned to date from the landmark Accountable Health Communities (AHC) Model test, which launched in 2017 and ended in April 2022.
|
|
-
CMS’ Quality Programs Bi-Monthly Forum will be held this Thursday, August 11 from 10– 11 PT. During this webinar, attendees will learn important updates relevant to CMS’s Quality Measurement and Value-Based Incentives Group (QMVIG).
|
|
-
Senate lawmakers voted 51-50 on Sunday to pass a spending package that would extend enhanced Affordable Care Act subsidies through 2025, allow HHS to negotiate prices for certain drugs under Medicare, require drugmakers to offer rebates to Medicare if their prices rise faster than the inflation rate, and cap monthly insulin out-of-pocket costs at $35 for Medicare beneficiaries. The Inflation Reduction Act, which will be sent to the House for a vote, will "save millions of people an average of $800 a year on health insurance premiums," said CMS Administrator Chiquita Brooks-LaSure.
|
|
-
The Advancing Telehealth Beyond COVID-19 Act passed the US House of Representatives on July 27th and goes to the Senate for consideration.
|
|
-
Nationwide launch of 988 the Suicide and Crisis Lifeline, which will provide lifesaving mental health care to people in crisis.
-
The National Committee for Quality Assurance said it has rolled out new and updated quality measures for the 2023 Healthcare Effectiveness Data and Information Set in line with its commitment to advance health equity. Major updates include the addition of race and ethnicity stratifications to several HEDIS measures, revision of pregnancy- or childbirth-related measures to make them more inclusive of pregnant people who do not identify as women, and creation of several new measures to address health issues such as diabetic care, pediatric dental care and social need screening and intervention.
|
|
-
The Community Oncology Alliance (COA) has been contacted by a reporter from MedPage Today who is working on a piece about PBMs forcing patients to switch to a PBM mail-order pharmacy. If your pharmacy has an example of this happening, the reporter would love to talk to you. This reporter is a friend of COA’s and it should be an easy interview. Please reply back directly to Nick Ferreyros nferreyros@coacancer.org who can help coordinate.
|
|
-
Study explores telehealth to assess frailty in patients with blood cancers. Among 185 patients with blood cancer ages 73 and older who were enrolled for virtual assessments to compare and measure frailty against 876 patients assessed in person, 81.1% successfully accomplished the online test and no injuries were reported, according to a study published in Blood Advances.
|
|
-
The Institute for Clinical and Economic Review (ICER) released a Final Evidence Report assessing the comparative clinical effectiveness and value of betibeglogene autotemcel (beti-cel, bluebird bio) for the treatment of beta thalassemia.
|
|
-
Global Blood Therapeutics invites you to their webinar on August 18, 2022 at 5pm PT, entitled “A Treatment Option for Sickle Cell Disease” presented by: Zahra Pakbaz, M.D., Associate Clinical Professor, Division of Hematology-Oncology Department of Medicine, UCI School of Medicine.
|
|
-
AstraZeneca Pharmaceuticals has made Evusheld available through Amerisource Bergen. If you are not in the health partner order portal (HPOP) for Covid-19, you are able to get a limited supply by filling out the EVUSHELD Small Volume Order Form. This form is exclusively for limited quantities (e.g. 3 patient courses) by smaller sites of care not currently being provided EVUSHELD via the HPOP distribution process.
|
|
-
Bayer HealthCare Pharmaceuticals Inc. announced that the FDA approved darolutamide (Nubeqa) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
-
Daiichi Sankyo, Inc. informed MOASC that the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH‑) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
